Your browser doesn't support javascript.
loading
Efficacy of Sacubitril-Valsartan on Survival and Cardiac Remodeling in Hypotensive Heart Failure With Reduced Ejection Fraction: A Multicenter Study.
Hsu, Chien-Yi; Chung, Fa-Po; Chao, Chieh-Ju; Chen, Ying-Ju; Wu, Cho-Kai; Wu, Yen-Wen; Huang, Jin-Long; Chu, Pao-Hsien; Jia-Yin Hou, Charles; Chang, Hung-Yu; Hung, Chung-Lieh.
Afiliação
  • Hsu CY; Division of Cardiology and Cardiovascular Research Center, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan; Division of Cardiology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Taipei Heart In
  • Chung FP; Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Chao CJ; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.
  • Chen YJ; Department of Telehealth, MacKay Memorial Hospital, Taipei, Taiwan.
  • Wu CK; Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Wu YW; Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
  • Huang JL; Cardiovascular Center, Department of Internal Medicine and Medical Education, Taichung Veterans General Hospital, Taichung, Taiwan.
  • Chu PH; Department of Cardiology, Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.
  • Jia-Yin Hou C; Division of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan.
  • Chang HY; Heart Center, Cheng Hsin General Hospital, Taipei, Taiwan. Electronic address: amadeus0814@yahoo.com.tw.
  • Hung CL; Department of Telehealth, MacKay Memorial Hospital, Taipei, Taiwan; Division of Cardiology, Department of Internal Medicine, MacKay Memorial Hospital, Taipei, Taiwan; Institute of Biomedical Sciences, MacKay Medical College, New Taipei, Taiwan. Electronic address: jotaro3791@gmail.com.
Mayo Clin Proc ; 99(6): 940-952, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38530689
ABSTRACT

OBJECTIVE:

To investigate whether hypotensive patients diagnosed with heart failure and reduced ejection fraction (HFrEF) might benefit from angiotensin receptor-neprilysin inhibitors (ARNis) in real-world practice because patients with baseline systolic blood pressure (SBP) of less than 100 mm Hg have been excluded from landmark trials. PATIENTS AND

METHODS:

In this multicenter study conducted between January 1, 2013, and December 31, 2021, a total of 7562 symptomatic patients with HFrEF were enrolled and grouped by SBP (hypotension was defined as an SBP of less than 100 mm Hg) and ARNi use as follows group 1, hypotensive/non-ARNi users (n=484); group 2, hypotensive/ARNi users (n=308); group 3, nonhypotensive/non-ARNi users (n=4560); and group 4, nonhypotensive/ARNi users (n=2210). Inverse probability of treatment weighting was used to balance baseline characteristics for survival analysis.

RESULTS:

Diverse baseline characteristics and lower rates of medication use were found among non-ARNi users compared with ARNi users. Hypotensive/ARNi users had lower ARNi initiation doses than nonhypotensive/ARNi users. We observed significantly lower mortality, composite heart failure hospitalization, and CV death for hypotensive/ARNi and the other 2 nonhypotensive groups (groups 3 and 4) during a median follow-up of 3.43 years (all P<.05), with a similar effect on reverse remodeling for the hypotensive/ARNi group compared with the hypotensive/non-ARNi group. The event-free survival benefits of ARNi vs renin-angiotensin system inhibitors were consistent with the lower boundary of SBP for clinical benefits found until 88 mm Hg (spline curves) after inverse probability of treatment weighting.

CONCLUSION:

Patients with HFrEF and hypotension may still benefit from ARNi treatment. Patients with hypotensive HFrEF should not be routinely excluded from ARNi use in a real-world setting.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Volume Sistólico / Compostos de Bifenilo / Remodelação Ventricular / Combinação de Medicamentos / Antagonistas de Receptores de Angiotensina / Valsartana / Aminobutiratos / Insuficiência Cardíaca / Hipotensão Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mayo Clin Proc Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 6_ODS3_enfermedades_notrasmisibles Base de dados: MEDLINE Assunto principal: Volume Sistólico / Compostos de Bifenilo / Remodelação Ventricular / Combinação de Medicamentos / Antagonistas de Receptores de Angiotensina / Valsartana / Aminobutiratos / Insuficiência Cardíaca / Hipotensão Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Mayo Clin Proc Ano de publicação: 2024 Tipo de documento: Article